Search the database for deliberate release of GM medicinal products

Displaying 1 - 3 of 3

EU record number	Title	Company / Sponsor	Treated organism	Genetic modification
B/BE/21/BVW8	Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene	Meira GTx UK II Limited	Humans	Non-replicating recombinant vector derived from adeno-associated virus AAV 5 carrying the human RPGR gene
Only notified under the "contained use" procedure. Dossier submitted on 28/10/2021.	A Phase I/II, First-in-human, open-label, accelerated-titration, two-part clinical trial of TK-8001 in patients with HLA-A*02:01 genotype and advanced-stage/metastatic, MAGE-A1 + solid tumors that either have no further approved therapeutic alternative(s)	T-Knife GmbH	Humans	chimere MAGE-A1 TCRs
B/BE/08/BVW1	MI-CP178: Study of a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month-Old Infants	MedImmune LLC	Humans	Genes of the human Parainfluenza virus fusion (F) and hemagglutinin-neuraminidase (HN) proteins; gene of the human Respiratory syncitial virus fusion protein (RSV F).